Xin Hua, Lin-Min Chen, Qian Zhu, Huan-Xin Lin and Ling Guo contributed equally to this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Pain due to oral mucositis (OM) is a major problem during concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) patients.
We enrolled 56 NPC patients receiving CCRT and allocated them into two groups: moderate pain group (n = 27) and a severe pain group (n = 29) according to the degree of pain reported (moderate = numerical rating scale (NRS) score 4–6 or severe = NRS score 7–10) at initiation of controlled-release oxycodone (CRO) treatment.
Total dose of CRO was significantly higher in severe pain patients than in moderate pain patients (791.60 ± 332.449 mg vs. 587.27 ± 194.940 mg; P = 0.015). Moderate pain patients had significantly better quality of life (P = 0.037), lower weight loss (P = 0.030) and more active CCRT response (90.9% vs. 64.0%; P = 0.041). Although 24-h pain control rate was comparable in the two groups (85.2% vs. 86.2%; P = 0.508), the moderate pain group score eventually stabilized at ~ 2 vs. 3 in the severe pain group (P < 0.001); the titration time to reach bearable pain (NRS ≤ 3) was also significantly shorter in moderate pain patients (2.45 ± 0.60 days vs. 3.60 ± 1.98 days; P = 0.012). Incidence of adverse events was comparable in both groups.
The study findings suggest that early introduction of low-dose CRO at the moderate pain stage could help reduce the total dose required, provide better pain control, improve quality of life, and enhance CCRT response.
Zhang LF, Li YH, Xie SH, Ling W, Chen SH, Liu Q, Huang QH, Cao SM (2015) Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis. Chin J Cancer 34(8):350–357. https://doi.org/10.1186/s40880-015-0018-6 CrossRefPubMed
Nishimura N, Nakano K, Ueda K, Kodaira M, Yamada S, Mishima Y, Yokoyama M, Terui Y, Takahashi S, Hatake K (2012) Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Support Care Cancer 20(9):2053–2059. https://doi.org/10.1007/s00520-011-1314-6 CrossRefPubMed
Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HS, Lee KS, Loong S, Sethi V, Chua EJ, Machin D (2005) Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23(27):6730–6738. https://doi.org/10.1200/JCO.2005.16.790 CrossRefPubMed
Yen SH, Wang LW, Lin YH, Jen YM, Chung YL (2012) Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 82(4):1463–1470. https://doi.org/10.1016/j.ijrobp.2011.04.029 CrossRefPubMed
Takase H, Sakata T, Yamano T, Sueta T, Nomoto S, Nakagawa T (2011) Advantage of early induction of opioid to control pain induced by irradiation in head and neck cancer patients. Auris Nasus Larynx 38(4):495–500. https://doi.org/10.1016/j.anl.2010.12.012 CrossRefPubMed
Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J (2012) Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 13(2):163–171. https://doi.org/10.1016/s1470-2045(11)70320-5 CrossRefPubMed
Liang G, Du W, Ke Q, Huang B, Yang J (2017) The effects of recombinant human granulocyte colony-stimulating factor mouthwash on radiotherapy-induced oral mucositis in locally advanced nasopharyngeal carcinoma patients. Adv Clin Exp Med 26(3):409–413. https://doi.org/10.17219/acem/61913 CrossRefPubMed
Luo Y, Feng M, Fan Z, Zhu X, Jin F, Li R, Wu J, Yang X, Jiang Q, Bai H, Huang Y, Lang J (2016) Effect of Kangfuxin solution on chemo/radiotherapy-induced mucositis in nasopharyngeal carcinoma patients: a multicenter, prospective randomized phase III clinical study. Evid Based Complement Alternat Med 2016:8692343. https://doi.org/10.1155/2016/8692343 CrossRefPubMedPubMedCentral
Zheng B, Zhu X, Liu M, Yang Z, Yang L, Lang J, Shi M, Wu G, He X, Chen X, Xi X, Zhao D, Zhu G (2018) Randomized, double-blind, placebo-controlled trial of Shuanghua Baihe tablets to prevent oral mucositis in patients with nasopharyngeal cancer undergoing chemoradiation therapy. Int J Radiat Oncol Biol Phys 100(2):418–426. https://doi.org/10.1016/j.ijrobp.2017.10.013 CrossRefPubMed
NCCN clinical practice guidelines in Oncology: Adult cancer pain ( Version1.2015) (2015)
Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13(2):e58–e68. https://doi.org/10.1016/s1470-2045(12)70040-2 CrossRefPubMed
Saunders DP, Epstein JB, Elad S, Allemano J, Bossi P, van de Wetering MD, Rao NG, Potting C, Cheng KK, Freidank A, Brennan MT, Bowen J, Dennis K, Lalla RV, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral O (2013) Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer 21(11):3191–3207. https://doi.org/10.1007/s00520-013-1871-y CrossRefPubMed
Miller M, Barber CW, Leatherman S, Fonda J, Hermos JA, Cho K, Gagnon DR (2015) Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med 175(4):608–615. https://doi.org/10.1001/jamainternmed.2014.8071 CrossRefPubMed
Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N, Ford I (1998) Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16(10):3222–3229. https://doi.org/10.1200/JCO.1918.104.22.16822 CrossRefPubMed
Hagen NA, Babul N (1997) Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 79(7):1428–1437 CrossRef
Pan H, Zhang Z, Zhang Y, Xu N, Lu L, Dou C, Guo Y, Wu S, Yue J, Wu D, Dai Y (2007) Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain. Clin Drug Investig 27(4):259–267 CrossRef
Gomes T, Jain S, Paterson JM, Sketris I, Caetano P, Henry D, Canadian Network for Observational Drug Effect Studies I (2018) Trends and uptake of new formulations of controlled-release oxycodone in Canada. Pharmacoepidemiol Drug Saf 27(5):520–525. https://doi.org/10.1002/pds.4390 CrossRefPubMedPubMedCentral
Zhou HD, Jiang HF, Zhu YJ, Fang J (2017) Clinical application of oxycodone combined with dexmedetomidine in percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinomas. Zhonghua Yi Xue Za Zhi 97(44):3480–3482. https://doi.org/10.3760/cma.j.issn.0376-2491.2017.44.009 CrossRefPubMed
Kalso E (2005) Oxycodone. J Pain Symptom Manag 29(5 Suppl):S47–S56. https://doi.org/10.1016/j.jpainsymman.2005.01.010 CrossRef
Kapil R, Nolting A, Roy P, Fiske W, Benedek I, Abramowitz W (2004) Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Clin Ther 26(12):2015–2025. https://doi.org/10.1016/j.clinthera.2004.12.013 CrossRefPubMed
Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J (2003) Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105(1–2):71–78 CrossRef
Hawker GA, Mian S, Kendzerska T, French M (2011) Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res 63(Suppl 11):S240–S252. https://doi.org/10.1002/acr.20543 CrossRef
Cancer Therapy Evaluation Program, Common terminology criteria for adverse events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS. (2003)
Mao YP, Xie FY, Liu LZ, Sun Y, Li L, Tang LL, Liao XB, Xu HY, Chen L, Lai SZ, Lin AH, Liu MZ, Ma J (2009) Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys 73(5):1326–1334. https://doi.org/10.1016/j.ijrobp.2008.07.062 CrossRefPubMed
Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS (2017) Oxycodone for cancer-related pain. Cochrane Database Syst Rev 8:CD003870. https://doi.org/10.1002/14651858.CD003870.pub6 CrossRefPubMed
Guo SP, Wu SG, Zhou J, Feng HX, Li FY, Wu YJ, Sun JY, He ZY (2014) Transdermal fentanyl for pain due to chemoradiotherapy-induced oral mucositis in nasopharyngeal cancer patients: evaluating efficacy, safety, and improvement in quality of life. Drug Des Devel Ther 8:497–503. https://doi.org/10.2147/DDDT.S60187 CrossRefPubMedPubMedCentral
Li W, Shen LJ, Chen T, Sun XQ, Zhang Y, Wu M, Shu WH, Chen C, Pan CC, Xia YF, Wu PH (2016) Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study. Chinese Journal of Cancer 35(1):75. https://doi.org/10.1186/s40880-016-0139-6 CrossRefPubMedPubMedCentral
Shen LJ, Chen C, Li BF, Gao J, Xia YF (2013) High weight loss during radiation treatment changes the prognosis in under-/normal weight nasopharyngeal carcinoma patients for the worse: a retrospective analysis of 2433 cases. PLoS One 8(7):e68660. https://doi.org/10.1371/journal.pone.0068660 CrossRefPubMedPubMedCentral
Guo SS, Hu W, Chen QY, Li JM, Zhu SH, He Y, Li JW, Xia L, Ji L, Lin CY, Liu LT, Tang LQ, Guo L, Mo HY, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Hong MH, Shao JY, Sun Y, Ma J, Fan YY, Mai HQ (2018) Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT. BMC Cancer 18(1):114. https://doi.org/10.1186/s12885-018-4003-8 CrossRefPubMedPubMedCentral
Coluzzi F, Mattia C (2005) Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol 71(7–8):451–460 PubMed
- Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial
- Springer Berlin Heidelberg
Supportive Care in Cancer
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II